Literature DB >> 12632027

Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis.

Karina Meijer1, Herman G D Hendriks, Joost Th M De Wolf, Ids J Klompmaker, Ton Lisman, Ans A M Hagenaars, Maarten J H Slooff, Robert J Porte, Jan van der Meer.   

Abstract

The effect of recombinant factor VIIa (rFVIIa) on blood loss was evaluated in cirrhotic patients undergoing orthotopic liver transplantation. In the present study, we explored the effect of rFVIIa on coagulation and fibrinolysis during orthotopic liver transplantation. Coagulation factors, parameters of thrombin generation and parameters of fibrinolysis were measured in six patients who had received a single dose of 80 micro g/kg rFVIIa and in ten controls, during and after orthotopic liver transplantation. Baseline concentrations and course of coagulation factors were similar in patients and controls. Thrombin generation did not rise after the administration of rFVIIa, but showed a sharp increase after reperfusion in patients, as compared with controls. No difference in fibrinolysis was apparent between patients and controls. No evidence of diffuse intravascular coagulation was seen. We conclude that the use of rFVIIa in orthotopic liver transplantation seems to enhance thrombin generation in a localized and time-limited matter, without causing systemic coagulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632027     DOI: 10.1097/01.mbc.0000046194.72384.99

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  7 in total

Review 1.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 2.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

3.  Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study.

Authors:  Char M Witmer; Yuan-Shung Huang; Kevin Lynch; Leslie J Raffini; Samir S Shah
Journal:  J Pediatr       Date:  2010-12-10       Impact factor: 4.406

Review 4.  Methods to decrease blood loss and transfusion requirements for liver transplantation.

Authors:  Kurinchi Selvan Gurusamy; Theodora Pissanou; Hynek Pikhart; Jessica Vaughan; Andrew K Burroughs; Brian R Davidson
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 5.  Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.

Authors:  Anthony E Pusateri; Myung S Park
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

6.  Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective.

Authors:  Jean-Louis Vincent; Rolf Rossaint; Bruno Riou; Yves Ozier; David Zideman; Donat R Spahn
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

Review 7.  The Advantages and Disadvantages of Methods Used to Control Liver Bleeding: A Review.

Authors:  Saeed Nouri; Mohammad Reza Sharif; Hasan Afzali; Alireza Sharif; Mojtaba Satkin
Journal:  Trauma Mon       Date:  2015-11-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.